SWEDISH ORPHAN BIOVITRUM LTD

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +30.6%

  £60,061,362 → £78,410,391

• Cash

  —

  Not reported

• Net assets

  +22.4%

  £19,277,032 → £23,600,296

• Employees

  +11.1%

  54 → 60

• Operating profit

  +14%

  £5,278,558 → £6,019,677

• Profit before tax

  +12%

  £5,382,036 → £6,027,655

• Wages

  +77.9%

  £7,261,114 → £12,919,531

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. SWEDISH ORPHAN BIOVITRUM LTD 2010-06-11 → present
2. SWEDISH ORPHAN INTERNATIONAL LTD 2002-08-30 → 2010-06-11
3. TRUNKSPACE LIMITED 2002-02-08 → 2002-08-30

Accounting basis

FRS 101

Reporting scope

Standalone (parent only)

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“As a wholly-owned subsidiary of the parent company, Swedish Orphan Biovitrum AB (Sobi AB), cash is managed through a group cash pooling arrangement. The company is therefore reliant on support from its parent and has obtained confirmation from its parent that it will continue to provide the necessary financial support to ensure the company is able to continue as a going concern, for the going concern period. The Directors have compiled a budget and cash flow forecast for the period to 31 December 2026 being the going concern review period based on levels of trading observed to date in 2025, and taking into account the pricing and funding arrangements between the company and its parent. The Directors remain confident in the existing product portfolio as well as anticipated revenues from products currently in the launch plan, and have set targets for the coming year based on anticipated revenue growth. No significant capital expenditure is anticipated in the review period. As such, the Directors perceive no significant cash flow risk to the business. The Sobi group continues to perform strongly throughout the world and record sales and profit growth year on year. This, combined with the financial support from Swedish Orphan Biovitrum AB, provides the Directors with assurance that the business can expect to continue as a going concern for the period to 31 December 2026. The Directors have made enquiries of its parent undertaking and are comfortable that the parent has the ability to provide financial support as needed.”

Significant events

• “There have been no significant events affecting the company since the reporting date.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.